Skip to main navigation Skip to search Skip to main content

A phase 3, open-label, randomized trial to evaluate the safety and efficacy of levofloxacin inhalation solution (APT-1026) versus tobramycin inhalation solution in stable cystic fibrosis patients

  • J. Stuart Elborn
  • , David E. Geller
  • , Douglas Conrad
  • , Shawn D. Aaron
  • , Alan R. Smyth
  • , Rainald Fischer
  • , Eitan Kerem
  • , Scott C. Bell
  • , Jeffery S. Loutit
  • , Michael N. Dudley
  • , Elizabeth E. Morgan
  • , Donald R. VanDevanter
  • , Patrick A. Flume*
  • *Corresponding author for this work

Research output: Contribution to journal › Article › peer-review

Abstract

Background: Inhaled antibiotics are standard of care for persons with cystic fibrosis (CF) and chronic Pseudomonas aeruginosa airway infection. APT-1026 (levofloxacin inhalation solution, LIS) is fluoroquinolone in development. We compared the safety and efficacy of LIS to tobramycin inhalation solution (TIS) in persons ≥ 12 years old with CF and chronic P. aeruginosa infection. 

Methods: This multinational, randomized (2:1), non-inferiority study compared LIS and TIS over three 28-day on/off cycles. Day 28 FEV1 % predicted relative change was the primary endpoint. Time to exacerbation and patient-reported quality of life were among secondary endpoints. 

Results: Baseline demographics for 282 subjects were comparable. Non-inferiority was demonstrated (1.86% predicted mean FEV1 difference [95% CI -0.66 to 4.39%]). LIS was well-tolerated, with dysgeusia (taste distortion) as the most frequent adverse event. 

Conclusions: LIS is a safe and effective therapy for the management of CF patients with chronic P. aeruginosa infection.

Original languageEnglish
Pages (from-to)507-514
Number of pages8
JournalJournal of Cystic Fibrosis
Volume14
Issue number4
Early online date24 Jun 2015
DOIs
Publication statusPublished - 01 Jul 2015

Bibliographical note

Publisher Copyright:
© 2014 European Cystic Fibrosis Society.

Keywords

  • Aerosol
  • Antibiotics
  • Cystic fibrosis
  • Fluoroquinolone
  • Pseudomonas

ASJC Scopus subject areas

  • Pediatrics, Perinatology, and Child Health
  • Pulmonary and Respiratory Medicine

Fingerprint

Dive into the research topics of 'A phase 3, open-label, randomized trial to evaluate the safety and efficacy of levofloxacin inhalation solution (APT-1026) versus tobramycin inhalation solution in stable cystic fibrosis patients'. Together they form a unique fingerprint.

Cite this